Key facts
- This page summarizes Robert Bindert Huizinga's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2022, 15:10.
Robert Bindert Huizinga - 02 Mar 2022 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- EVP of Research
- Issuer ticker
- AUPH
- Reported as of
- 02 Mar 2022
- Net transaction value
- -$58,236
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2022, 15:10:07 UTC
- Prior SEC filing
- 26 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Bindert Huizinga
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Bindert Huizinga filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 04 Mar 2022.
Change
- Previous filing in this sequence was filed on 26 Oct 2021.
- Current net transaction value: -$58,236.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,500
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 74,228
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
AUPH
transaction
Common Stock
Sale
- Transaction value
- $58,236
- Shares
- -4,849
- Change %
- -6.5%
- Price
- $12.01
- Shares after
- 69,379
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUPH
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +62,448
- Change %
- Price
- $0.000000
- Shares after
- 62,448
- Date
- 02 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 62,448
- Exercise price
- Footnotes
- F3
AUPH
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +106,838
- Change %
- Price
- $0.000000
- Shares after
- 106,838
- Date
- 02 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 106,838
- Exercise price
- $12.01
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
Footnote F2
Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
Footnote F3
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
Footnote F4
One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.